Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

University of Toronto

$137,209.00

Cross-linked polyester-based depot systems for sustained drug delivery: determining the relationship between composition, properties and performance

FY 2018-19

Summary
There are currently more than 20 pharmaceutical products that include implantable, insertable or injectable*drug delivery systems that are formed from the copolymer poly(lactide-co-glycolide) (PLGA) and provide*sustained release of drug therapy over time. The sustained drug release that is achieved with a single*administration, eliminates the need for daily or weekly drug administrations and as a result has a profoundly*positive impact on a patient's quality of life, patient compliance and leads to significant reductions in health*care costs. These products are currently used to treat critical medical conditions including diabetes,*endometriosis, prostate cancer and schizophrenia. While PLGA-based systems have provided a delivery*solution to many drugs, it is clear, a new polymeric delivery system is needed to meet the needs of the*pharmaceutical industry. Given that each drug is unique in terms of its physico-chemical properties and that*polymer-drug interaction and compatibility are key metrics that influence the performance of polymeric*delivery formulations there is no single polymer that can serve as a universal material for formulation of all*drugs. For this reason, Pendant Biosciences (a Canadian company) has patented, and in collaboration with the*Allen laboratory filed an additional provisional patent application, on a flexible polymer platform that includes*recognized building blocks that produce cross-linked biocompatible systems for prolonged delivery of a wide*range of drugs. If successful, the proposed research will result in (1) identification of a lead drug-polymer*product for development by Pendant Biosciences; (2) a 'tool-box' of biocompatible polymer materials to*facilitate drug-delivery research in academic and industrial settings and (3) increased scientific awareness of*the physical and chemical metrics responsible for the performance of a drug-polymer combination product.
Program
Collaborative Research and Development Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
508274-2017
Name nom
Allen, Christine
Department département
Pharmacy, Leslie Dan Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
137209
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
2000
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Materials science and technology
Research subject fr
Science et technologie des matériaux
Partie
2
Nb partie
2
Application title
Cross-linked polyester-based depot systems for sustained drug delivery: determining the relationship between composition, properties and performance
Keyword
NSERC
Application summary
There are currently more than 20 pharmaceutical products that include implantable, insertable or injectable*drug delivery systems that are formed from the copolymer poly(lactide-co-glycolide) (PLGA) and provide*sustained release of drug therapy over time. The sustained drug release that is achieved with a single*administration, eliminates the need for daily or weekly drug administrations and as a result has a profoundly*positive impact on a patient's quality of life, patient compliance and leads to significant reductions in health*care costs. These products are currently used to treat critical medical conditions including diabetes,*endometriosis, prostate cancer and schizophrenia. While PLGA-based systems have provided a delivery*solution to many drugs, it is clear, a new polymeric delivery system is needed to meet the needs of the*pharmaceutical industry. Given that each drug is unique in terms of its physico-chemical properties and that*polymer-drug interaction and compatibility are key metrics that influence the performance of polymeric*delivery formulations there is no single polymer that can serve as a universal material for formulation of all*drugs. For this reason, Pendant Biosciences (a Canadian company) has patented, and in collaboration with the*Allen laboratory filed an additional provisional patent application, on a flexible polymer platform that includes*recognized building blocks that produce cross-linked biocompatible systems for prolonged delivery of a wide*range of drugs. If successful, the proposed research will result in (1) identification of a lead drug-polymer*product for development by Pendant Biosciences; (2) a 'tool-box' of biocompatible polymer materials to*facilitate drug-delivery research in academic and industrial settings and (3) increased scientific awareness of*the physical and chemical metrics responsible for the performance of a drug-polymer combination product.
University of Toronto - $137,209 Grant (2018-19) | Canada Spends